SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study

Background and Objective: Evaluating vaccine effectiveness (VE) is essential to implementing prevention strategies, and our objective was to estimate the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines in preventing SARS-CoV-2 infection. Materials and Methods: We carried out a population-based, prosp...

Descripción completa

Detalles Bibliográficos
Autores: Domènech-Montoliu, S, Pérez-Olaso, O, Sala-Trull, D, Del Rio-Gonzalez, A, López-Diago, L, Aleixandre-Gorriz, I, Pac-Sa, MR, Sánchez-Urbano, M, Satorres-Martinez, P, Notari-Rodriguez, C, Casanova-Suárez, J, Ruiz-Puig, R, Badenes-Marques, G, Aparisi-Esteve, L, Domènech-León, C, Romeu-Garcia, MA, Arnedo-Pena, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Málaga
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::5f44b06ec58c38d82bcad8e6e3cf6728
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/20414
Access Level:acceso abierto
Palabra clave:COVID-19
SARS-CoV-2 infection
SARS-CoV-2 mRNA vaccines
vaccine effectiveness
symptomatic
asymptomatic
prospective cohort
population-based
id ES_00778a6f1bab7e7db4aa2bdb7cce03a2
oai_identifier_str oai:dnet:r-fisabio___::5f44b06ec58c38d82bcad8e6e3cf6728
network_acronym_str ES
network_name_str España
repository_id_str
spelling SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort StudyDomènech-Montoliu, SPérez-Olaso, OSala-Trull, DDel Rio-Gonzalez, ALópez-Diago, LAleixandre-Gorriz, IPac-Sa, MRSánchez-Urbano, MSatorres-Martinez, PNotari-Rodriguez, CCasanova-Suárez, JRuiz-Puig, RBadenes-Marques, GAparisi-Esteve, LDomènech-León, CRomeu-Garcia, MAArnedo-Pena, ACOVID-19SARS-CoV-2 infectionSARS-CoV-2 mRNA vaccinesvaccine effectivenesssymptomaticasymptomaticprospective cohortpopulation-basedBackground and Objective: Evaluating vaccine effectiveness (VE) is essential to implementing prevention strategies, and our objective was to estimate the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines in preventing SARS-CoV-2 infection. Materials and Methods: We carried out a population-based, prospective cohort study on the Borriana COVID-19 cohort (Valencia Community, Spain) during the 2021-2023 period, considering all SARS-CoV-2 cases that occurred after the SARS-CoV-2 vaccine campaign started in January 2021 (first approach), as well as only symptomatic cases (second approach). Multivariable robust Poisson regression models were employed. Results: In this cohort with 301 participants, 285 were vaccinated, among whom 228 received only SARS-CoV-2 mRNA vaccines, and 57 received mRNA vaccines and other vaccines. In the first approach, there were 226 cases and 75 non-cases. The adjusted VE for three doses of vaccine was 37% (95% confidence interval [CI]: 22-49%) to prevent infection. In the second approach, with 153 symptomatic cases after excluding 73 asymptomatic cases, the adjusted VE for three doses of vaccine was 50% (95% CI 33-63%) to prevent symptomatic infection. Three doses of vaccine exhibited modest but significant protection against infection and symptomatic infection. Conclusions: This study recommends surveilling SARS-CoV-2 infections and variants, vaccinating at-risk populations, and developing new vaccines.MDPI2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/20414EpidemiologiaISSN: 26733986reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Universidad de MálagaInglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::5f44b06ec58c38d82bcad8e6e3cf67282026-06-11T12:45:17Z
dc.title.none.fl_str_mv SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
title SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
spellingShingle SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Domènech-Montoliu, S
COVID-19
SARS-CoV-2 infection
SARS-CoV-2 mRNA vaccines
vaccine effectiveness
symptomatic
asymptomatic
prospective cohort
population-based
title_short SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
title_full SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
title_fullStr SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
title_full_unstemmed SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
title_sort SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
dc.creator.none.fl_str_mv Domènech-Montoliu, S
Pérez-Olaso, O
Sala-Trull, D
Del Rio-Gonzalez, A
López-Diago, L
Aleixandre-Gorriz, I
Pac-Sa, MR
Sánchez-Urbano, M
Satorres-Martinez, P
Notari-Rodriguez, C
Casanova-Suárez, J
Ruiz-Puig, R
Badenes-Marques, G
Aparisi-Esteve, L
Domènech-León, C
Romeu-Garcia, MA
Arnedo-Pena, A
author Domènech-Montoliu, S
author_facet Domènech-Montoliu, S
Pérez-Olaso, O
Sala-Trull, D
Del Rio-Gonzalez, A
López-Diago, L
Aleixandre-Gorriz, I
Pac-Sa, MR
Sánchez-Urbano, M
Satorres-Martinez, P
Notari-Rodriguez, C
Casanova-Suárez, J
Ruiz-Puig, R
Badenes-Marques, G
Aparisi-Esteve, L
Domènech-León, C
Romeu-Garcia, MA
Arnedo-Pena, A
author_role author
author2 Pérez-Olaso, O
Sala-Trull, D
Del Rio-Gonzalez, A
López-Diago, L
Aleixandre-Gorriz, I
Pac-Sa, MR
Sánchez-Urbano, M
Satorres-Martinez, P
Notari-Rodriguez, C
Casanova-Suárez, J
Ruiz-Puig, R
Badenes-Marques, G
Aparisi-Esteve, L
Domènech-León, C
Romeu-Garcia, MA
Arnedo-Pena, A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
SARS-CoV-2 infection
SARS-CoV-2 mRNA vaccines
vaccine effectiveness
symptomatic
asymptomatic
prospective cohort
population-based
topic COVID-19
SARS-CoV-2 infection
SARS-CoV-2 mRNA vaccines
vaccine effectiveness
symptomatic
asymptomatic
prospective cohort
population-based
description Background and Objective: Evaluating vaccine effectiveness (VE) is essential to implementing prevention strategies, and our objective was to estimate the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines in preventing SARS-CoV-2 infection. Materials and Methods: We carried out a population-based, prospective cohort study on the Borriana COVID-19 cohort (Valencia Community, Spain) during the 2021-2023 period, considering all SARS-CoV-2 cases that occurred after the SARS-CoV-2 vaccine campaign started in January 2021 (first approach), as well as only symptomatic cases (second approach). Multivariable robust Poisson regression models were employed. Results: In this cohort with 301 participants, 285 were vaccinated, among whom 228 received only SARS-CoV-2 mRNA vaccines, and 57 received mRNA vaccines and other vaccines. In the first approach, there were 226 cases and 75 non-cases. The adjusted VE for three doses of vaccine was 37% (95% confidence interval [CI]: 22-49%) to prevent infection. In the second approach, with 153 symptomatic cases after excluding 73 asymptomatic cases, the adjusted VE for three doses of vaccine was 50% (95% CI 33-63%) to prevent symptomatic infection. Three doses of vaccine exhibited modest but significant protection against infection and symptomatic infection. Conclusions: This study recommends surveilling SARS-CoV-2 infections and variants, vaccinating at-risk populations, and developing new vaccines.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/20414
url https://fisabio.portalinvestigacion.com/publicaciones/20414
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Epidemiologia
ISSN: 26733986
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Universidad de Málaga
instname_str Universidad de Málaga
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402501988483072
score 15.812429

Similares en LA Referencia